Clinical trial results:
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA™ Once-Daily in Treatment-Naïve HIV-1 Infected Subjects

Summary

EudraCT number	2014-003382-17
Trial protocol	DE GB PT DK NL BE ES
Global end of trial date	07 September 2023

Results information

Result version number	v1 (current)
This version publication date	07 September 2024
First version publication date	07 September 2024

Trial information

Trial identification

Sponsor protocol code	MK-1439A-021

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02403674
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Merck Sharp & Dohme LLC
Sponsor organisation address	126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ, United States, 07065
Public contact	Clinical Trials Disclosure, Merck Sharp & Dohme LLC, ClinicalTrialsDisclosure@merck.com
Scientific contact	Clinical Trials Disclosure, Merck Sharp & Dohme LLC, ClinicalTrialsDisclosure@merck.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	07 September 2023
Is this the analysis of the primary completion data?	Yes
Primary completion date	20 March 2017
Global end of trial reached?	Yes
Global end of trial date	07 September 2023
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The purpose of this study was to compare the antiretroviral activity of doravirine, tenofovir, lamivudine (MK-1439A), a single-tablet, once-daily (q.d.) fixed-dose combination (FDC) containing doravirine (DOR) 100 mg + lamivudine (3TC) 300 mg + tenofovir disoproxil fumarate (TDF) 300 mg, with ATRIPLA™, a single-tablet FDC containing efavirenz 600 mg + emtricitabine 200 mg + tenofovir disoproxil fumarate 300 mg, in treatment-naive participants infected with human immunodeficiency virus (HIV). The primary hypothesis was that doravirine, tenofovir, lamivudine q.d. is non-inferior to ATRIPLA™ q.d. as assessed by the proportion of participants with HIV-1 ribonucleic acid (RNA) <50 copies/mL (by the Abbott RealTime HIV-1 Assay) at Week 48.

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	05 June 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 3
Country: Number of subjects enrolled	Belgium: 7
Country: Number of subjects enrolled	Canada: 12
Country: Number of subjects enrolled	Chile: 49
Country: Number of subjects enrolled	Colombia: 41
Country: Number of subjects enrolled	Denmark: 6
Country: Number of subjects enrolled	Germany: 25
Country: Number of subjects enrolled	Guatemala: 20
Country: Number of subjects enrolled	Honduras: 7
Country: Number of subjects enrolled	Israel: 5
Country: Number of subjects enrolled	Mexico: 27
Country: Number of subjects enrolled	New Zealand: 7
Country: Number of subjects enrolled	Peru: 32
Country: Number of subjects enrolled	Portugal: 27
Country: Number of subjects enrolled	Russian Federation: 54
Country: Number of subjects enrolled	South Africa: 66

Country: Number of subjects enrolled	Spain: 16
Country: Number of subjects enrolled	Switzerland: 11
Country: Number of subjects enrolled	Taiwan: 37
Country: Number of subjects enrolled	Thailand: 74
Country: Number of subjects enrolled	United Kingdom: 32
Country: Number of subjects enrolled	United States: 176
Worldwide total number of subjects	734
EEA total number of subjects	81

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	730
From 65 to 84 years	4
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Treatment-naïve participants with HIV-1 infection have been recruited at 141 study sites worldwide. The present results include results from the base study (first 96-weeks of the study) along with study extension 1 (week 96 - 192), study extension 2 (week 192 - 288), and study extension 3 (week 288 - 384).

Pre-assignment

Screening details:

Randomization in base study was stratified by screening HIV-1 ribonucleic acid (RNA [≤1000,000 or >100,000 copies/mL]), and Chronic Hepatitis B and/or C infection status (yes or no).

Period 1

Period 1 title	Base Study
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	MK-1439A (DOR/3TC/TDF from Day 1)

Arm description:

Treatment-naive participants with HIV-1 infection took MK-1439A, a single-tablet fixed dose combination (FDC) containing doravirine (DOR) 100 mg + lamivudine (3TC) 300 mg + tenofovir disoproxil fumarate (TDF) 300 mg, once daily (q.d.) by mouth for 96 weeks. Participants also took 1 placebo tablet matched to ATRIPLA™ q.d. by mouth for 96 weeks in order to maintain blinding. Eligible participants from the Base Study (Day 1 to Week 96) may have entered open-label optional study extensions to receive MK-1439A (FDC containing DOR 100 mg + 3TC 300 mg + TDF 300 mg), taken q.d. during Study Extension 1 (Weeks 96 to 192), Extension 2 (Weeks 192 to 288), and Extension 3 (Weeks 288 to 384).

Arm type	Active comparator
Investigational medicinal product name	Doravirine, Tenofovir, Lamivudine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

One doravirine, tenofovir, lamivudine tablet taken q.d. by mouth.

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Placebo tablets matched to ATRIPLA™ q.d.

Arm title	ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)

Arm description:

Treatment-naive participants with HIV-1 infection took ATRIPLA™, a single-tablet FDC containing efavirenz (EFV) 600 mg + emtricitabine (FTC) 200 mg + tenofovir disoproxil fumarate (TDF) 300 mg (equivalent to 245 mg tenofovir disoproxil), q.d. by mouth for 96 weeks. Participants also took 1 placebo tablet matched to MK-1439A q.d. by mouth for 96 weeks in order to maintain blinding. Eligible participants from the Base Study (Day 1 to Week 96) may have entered open-label optional study extensions to receive MK-1439A (FDC containing DOR 100 mg + 3TC 300 mg + TDF 300 mg), taken q.

d. during Study Extension 1 (Weeks 96 to 192), Extension 2 (Weeks 192 to 288), and Extension 3 (Weeks 288 to 384).

Arm type	Experimental
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Placebo tablets matched to doravirine, tenofovir, lamivudine.

Investigational medicinal product name	ATRIPLA™
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

One ATRIPLA™ tablet taken by mouth.

Number of subjects in period 1	MK-1439A (DOR/3TC/TDF from Day 1)	ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)
Started	368	366
Treated	364	364
Completed	296	276
Not completed	72	90
Consent withdrawn by subject	10	17
Physician decision	2	2
Adverse event, non-fatal	11	26
Death	1	4
Pregnancy	2	2
Noncompliance with study drug	1	4
Not treated with study drug	4	2
Lost to follow-up	6	8
Lack of efficacy	31	23
Protocol deviation	4	2

Period 2

Period 2 title	Study Extension 1 (Open-Label)
Is this the baseline period?	No
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	MK-1439A (DOR/3TC/TDF from Day 1)

Arm description:

Treatment-naive participants with HIV-1 infection took MK-1439A, a single-tablet fixed dose combination (FDC) containing doravirine (DOR) 100 mg + lamivudine (3TC) 300 mg + tenofovir disoproxil fumarate (TDF) 300 mg, once daily (q.d.) by mouth for 96 weeks. Participants also took 1 placebo tablet matched to ATRIPLA™ q.d. by mouth for 96 weeks in order to maintain blinding. Eligible participants from the Base Study (Day 1 to Week 96) may have entered open-label optional study extensions to receive MK-1439A (FDC containing DOR 100 mg + 3TC 300 mg + TDF 300 mg), taken q.d. during Study Extension 1 (Weeks 96 to 192), Extension 2 (Weeks 192 to 288), and Extension 3 (Weeks 288 to 384).

Arm type	Active comparator
Investigational medicinal product name	Doravirine, Tenofovir, Lamivudine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

One doravirine, tenofovir, lamivudine tablet taken q.d. by mouth.

Arm title	ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)

Arm description:

Treatment-naive participants with HIV-1 infection took ATRIPLA™, a single-tablet FDC containing efavirenz (EFV) 600 mg + emtricitabine (FTC) 200 mg + tenofovir disoproxil fumarate (TDF) 300 mg (equivalent to 245 mg tenofovir disoproxil), q.d. by mouth for 96 weeks. Participants also took 1 placebo tablet matched to MK-1439A q.d. by mouth for 96 weeks in order to maintain blinding. Eligible participants from the Base Study (Day 1 to Week 96) may have entered open-label optional study extensions to receive MK-1439A (FDC containing DOR 100 mg + 3TC 300 mg + TDF 300 mg), taken q.d. during Study Extension 1 (Weeks 96 to 192), Extension 2 (Weeks 192 to 288), and Extension 3 (Weeks 288 to 384).

Arm type	Experimental
Investigational medicinal product name	Doravirine, Tenofovir, Lamivudine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

One doravirine, tenofovir, lamivudine tablet taken q.d. by mouth.

Number of subjects in period 2[1]	MK-1439A (DOR/3TC/TDF from Day 1)	ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)
Started	291	269
Completed	230	205
Not completed	61	64
Physician decision	2	5
Consent withdrawn by subject	11	13
Adverse event, non-fatal	1	4
Availability of study drug locally	22	19
Death	1	-

Pregnancy	4	2
Non-Compliance with study drug	2	3
Lost to follow-up	8	5
Lack of efficacy	10	13

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.
Justification: not all study participants continued into optional study extension 1.

Period 3

Period 3 title	Study Extension 2 (Open-Label)
Is this the baseline period?	No
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	MK-1439A (DOR/3TC/TDF from Day 1)

Arm description:

Treatment-naive participants with HIV-1 infection took MK-1439A, a single-tablet fixed dose combination (FDC) containing doravirine (DOR) 100 mg + lamivudine (3TC) 300 mg + tenofovir disoproxil fumarate (TDF) 300 mg, once daily (q.d.) by mouth for 96 weeks. Participants also took 1 placebo tablet matched to ATRIPLA™ q.d. by mouth for 96 weeks in order to maintain blinding. Eligible participants from the Base Study (Day 1 to Week 96) may have entered open-label optional study extensions to receive MK-1439A (FDC containing DOR 100 mg + 3TC 300 mg + TDF 300 mg), taken q.d. during Study Extension 1 (Weeks 96 to 192), Extension 2 (Weeks 192 to 288), and Extension 3 (Weeks 288 to 384).

Arm type	Experimental
Investigational medicinal product name	Doravirine, Tenofovir, Lamivudine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

One doravirine, tenofovir, lamivudine tablet taken q.d. by mouth

Arm title	ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)

Arm description:

Treatment-naive participants with HIV-1 infection took ATRIPLA™, a single-tablet FDC containing efavirenz (EFV) 600 mg + emtricitabine (FTC) 200 mg + tenofovir disoproxil fumarate (TDF) 300 mg (equivalent to 245 mg tenofovir disoproxil), q.d. by mouth for 96 weeks. Participants also took 1 placebo tablet matched to MK-1439A q.d. by mouth for 96 weeks in order to maintain blinding. Eligible participants from the Base Study (Day 1 to Week 96) may have entered open-label optional study extensions to receive MK-1439A (FDC containing DOR 100 mg + 3TC 300 mg + TDF 300 mg), taken q.d. during Study Extension 1 (Weeks 96 to 192), Extension 2 (Weeks 192 to 288), and Extension 3 (Weeks 288 to 384).

Arm type	Active comparator
Investigational medicinal product name	Doravirine, Tenofovir, Lamivudine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

One doravirine, tenofovir, lamivudine tablet taken q.d. by mouth

Number of subjects in period 3[2]	MK-1439A (DOR/3TC/TDF from Day 1)	ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)
Started	192	173
Completed	150	132
Not completed	42	41
Physician decision	1	1
Consent withdrawn by subject	8	6
Availability of study drug locally	27	23
Death	2	2
Pregnancy	-	1
Non-Compliance with study drug	2	-
Lost to follow-up	1	7
Lack of efficacy	1	1

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.
Justification: not all study participants continued into optional study extension 2.

Period 4

Period 4 title	Study Extension 3 (Open-Label)
Is this the baseline period?	No
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	MK-1439A (DOR/3TC/TDF from Day 1)

Arm description:

Treatment-naive participants with HIV-1 infection took MK-1439A, a single-tablet fixed dose combination (FDC) containing doravirine (DOR) 100 mg + lamivudine (3TC) 300 mg + tenofovir disoproxil fumarate (TDF) 300 mg, once daily (q.d.) by mouth for 96 weeks. Participants also took 1 placebo tablet matched to ATRIPLA™ q.d. by mouth for 96 weeks in order to maintain blinding. Eligible participants from the Base Study (Day 1 to Week 96) may have entered open-label optional study extensions to receive MK-1439A (FDC containing DOR 100 mg + 3TC 300 mg + TDF 300 mg), taken q.d. during Study Extension 1 (Weeks 96 to 192), Extension 2 (Weeks 192 to 288), and Extension 3 (Weeks 288 to 384).

Arm type	Experimental
Investigational medicinal product name	Doravirine, Tenofovir, Lamivudine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

One doravirine, tenofovir, lamivudine tablet taken q.d. by mouth

Arm title	ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)

Arm description:

Treatment-naive participants with HIV-1 infection took ATRIPLA™, a single-tablet FDC containing efavirenz (EFV) 600 mg + emtricitabine (FTC) 200 mg + tenofovir disoproxil fumarate (TDF) 300 mg (equivalent to 245 mg tenofovir disoproxil), q.d. by mouth for 96 weeks. Participants also took 1 placebo tablet matched to MK-1439A q.d. by mouth for 96 weeks in order to maintain blinding. Eligible participants from the Base Study (Day 1 to Week 96) may have entered open-label optional study extensions to receive MK-1439A (FDC containing DOR 100 mg + 3TC 300 mg + TDF 300 mg), taken q.d. during Study Extension 1 (Weeks 96 to 192), Extension 2 (Weeks 192 to 288), and Extension 3 (Weeks 288 to 384).

Arm type	Active comparator
Investigational medicinal product name	Doravirine, Tenofovir, Lamivudine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

One doravirine, tenofovir, lamivudine tablet taken q.d. by mouth

Number of subjects in period 4[3]	MK-1439A (DOR/3TC/TDF from Day 1)	ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)
Started	121	111
Completed	100	85
Not completed	21	26
Physician decision	1	5
Consent withdrawn by subject	1	3
Availability of study drug locally	14	13
Pregnancy	-	1
Lost to follow-up	5	4

Notes:

[3] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.
Justification: not all study participants continued into optional study extension 3.

Baseline characteristics

Reporting groups

Reporting group title	MK-1439A (DOR/3TC/TDF from Day 1)

Reporting group description:

Treatment-naive participants with HIV-1 infection took MK-1439A, a single-tablet fixed dose combination (FDC) containing doravirine (DOR) 100 mg + lamivudine (3TC) 300 mg + tenofovir disoproxil fumarate (TDF) 300 mg, once daily (q.d.) by mouth for 96 weeks. Participants also took 1 placebo tablet matched to ATRIPLA™ q.d. by mouth for 96 weeks in order to maintain blinding. Eligible participants from the Base Study (Day 1 to Week 96) may have entered open-label optional study extensions to receive MK-1439A (FDC containing DOR 100 mg + 3TC 300 mg + TDF 300 mg), taken q.d. during Study Extension 1 (Weeks 96 to 192), Extension 2 (Weeks 192 to 288), and Extension 3 (Weeks 288 to 384).

Reporting group title	ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)

Reporting group description:

Treatment-naive participants with HIV-1 infection took ATRIPLA™, a single-tablet FDC containing efavirenz (EFV) 600 mg + emtricitabine (FTC) 200 mg + tenofovir disoproxil fumarate (TDF) 300 mg (equivalent to 245 mg tenofovir disoproxil), q.d. by mouth for 96 weeks. Participants also took 1 placebo tablet matched to MK-1439A q.d. by mouth for 96 weeks in order to maintain blinding. Eligible participants from the Base Study (Day 1 to Week 96) may have entered open-label optional study extensions to receive MK-1439A (FDC containing DOR 100 mg + 3TC 300 mg + TDF 300 mg), taken q.d. during Study Extension 1 (Weeks 96 to 192), Extension 2 (Weeks 192 to 288), and Extension 3 (Weeks 288 to 384).

Reporting group values	MK-1439A (DOR/3TC/TDF from Day 1)	ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)	Total
Number of subjects	368	366	734
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	366	364	730
From 65-84 years	2	2	4
85 years and over	0	0	0
Age Continuous Units: Years			
arithmetic mean	33.6	32.7	
standard deviation	± 10.5	± 9.9	-
Sex: Female, Male Units: Participants			
Female	59	54	113
Male	309	312	621
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	9	6	15
Asian	59	64	123
Native Hawaiian or Other Pacific Islander	0	0	0

Black or African American	70	69	139
White	178	171	349
More than one race	52	56	108
Unknown or Not Reported	0	0	0
Baseline cluster of differentiation 4 (CD4) cell counts			
The mean change from baseline in CD4 cell counts at Week 48 was assessed using the Observed Failure (OF) approach. With the OF approach, baseline values were carried forward for participants who discontinued prior to Week 48 due to lack of efficacy.			
Units: cells/mm^3			
arithmetic mean	434.9	415.5	
standard deviation	± 217.9	± 210.6	-
Baseline fasting low-density lipoprotein cholesterol (LDL-C)			
Participants fasted for ≥8 hours prior to LDL-C measurement on Day 1. The analysis population consisted of all randomized participants with baseline data available.			
Units: mg/dL			
arithmetic mean	92.08	90.47	
standard deviation	± 32.32	± 30.64	-
Baseline fasting non-high-density lipoprotein cholesterol (non-HDL-C)			
Participants fasted for ≥8 hours prior to non-HDL-C measurement on Day 1. The analysis population consisted of all randomized participants with baseline data available.			
Units: mg/dL			
arithmetic mean	115.39	114.63	
standard deviation	± 34.67	± 33.55	-
Baseline fasting cholesterol			
Participants fasted for ≥8 hours prior to cholesterol measurement on Day 1. The analysis population consisted of all randomized participants with baseline data available.			
Units: mg/dL			
arithmetic mean	157.29	156.07	
standard deviation	± 36.43	± 36.51	-
Baseline fasting triglycerides			
Participants fasted for ≥8 hour prior to triglycerides measurement on Day 1. The analysis population consisted of all randomized participants with baseline data available.			
Units: mg/dL			
arithmetic mean	120.85	123.23	
standard deviation	± 83.06	± 82.73	-
Baseline fasting high-density lipoprotein cholesterol (HDL-C)			
Participants fasted for ≥8 hours prior to HDL-C measurement on Day 1. Description: Participants fasted for ≥8 hours prior to HDL-C measurement on Day 1. The analysis population consisted of all randomized participants with baseline data available.			
Units: mg/dL			
arithmetic mean	41.90	41.44	
standard deviation	± 11.67	± 13.08	-

End points reporting groups

Reporting group title	MK-1439A (DOR/3TC/TDF from Day 1)

Reporting group description:

Treatment-naive participants with HIV-1 infection took MK-1439A, a single-tablet fixed dose combination (FDC) containing doravirine (DOR) 100 mg + lamivudine (3TC) 300 mg + tenofovir disoproxil fumarate (TDF) 300 mg, once daily (q.d.) by mouth for 96 weeks. Participants also took 1 placebo tablet matched to ATRIPLA™ q.d. by mouth for 96 weeks in order to maintain blinding. Eligible participants from the Base Study (Day 1 to Week 96) may have entered open-label optional study extensions to receive MK-1439A (FDC containing DOR 100 mg + 3TC 300 mg + TDF 300 mg), taken q.d. during Study Extension 1 (Weeks 96 to 192), Extension 2 (Weeks 192 to 288), and Extension 3 (Weeks 288 to 384).

Reporting group title	ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)

Reporting group description:

Treatment-naive participants with HIV-1 infection took ATRIPLA™, a single-tablet FDC containing efavirenz (EFV) 600 mg + emtricitabine (FTC) 200 mg + tenofovir disoproxil fumarate (TDF) 300 mg (equivalent to 245 mg tenofovir disoproxil), q.d. by mouth for 96 weeks. Participants also took 1 placebo tablet matched to MK-1439A q.d. by mouth for 96 weeks in order to maintain blinding. Eligible participants from the Base Study (Day 1 to Week 96) may have entered open-label optional study extensions to receive MK-1439A (FDC containing DOR 100 mg + 3TC 300 mg + TDF 300 mg), taken q.d. during Study Extension 1 (Weeks 96 to 192), Extension 2 (Weeks 192 to 288), and Extension 3 (Weeks 288 to 384).

Reporting group title	MK-1439A (DOR/3TC/TDF from Day 1)

Reporting group description:

Treatment-naive participants with HIV-1 infection took MK-1439A, a single-tablet fixed dose combination (FDC) containing doravirine (DOR) 100 mg + lamivudine (3TC) 300 mg + tenofovir disoproxil fumarate (TDF) 300 mg, once daily (q.d.) by mouth for 96 weeks. Participants also took 1 placebo tablet matched to ATRIPLA™ q.d. by mouth for 96 weeks in order to maintain blinding. Eligible participants from the Base Study (Day 1 to Week 96) may have entered open-label optional study extensions to receive MK-1439A (FDC containing DOR 100 mg + 3TC 300 mg + TDF 300 mg), taken q.d. during Study Extension 1 (Weeks 96 to 192), Extension 2 (Weeks 192 to 288), and Extension 3 (Weeks 288 to 384).

Reporting group title	ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)

Reporting group description:

Treatment-naive participants with HIV-1 infection took ATRIPLA™, a single-tablet FDC containing efavirenz (EFV) 600 mg + emtricitabine (FTC) 200 mg + tenofovir disoproxil fumarate (TDF) 300 mg (equivalent to 245 mg tenofovir disoproxil), q.d. by mouth for 96 weeks. Participants also took 1 placebo tablet matched to MK-1439A q.d. by mouth for 96 weeks in order to maintain blinding. Eligible participants from the Base Study (Day 1 to Week 96) may have entered open-label optional study extensions to receive MK-1439A (FDC containing DOR 100 mg + 3TC 300 mg + TDF 300 mg), taken q.d. during Study Extension 1 (Weeks 96 to 192), Extension 2 (Weeks 192 to 288), and Extension 3 (Weeks 288 to 384).

Reporting group title	MK-1439A (DOR/3TC/TDF from Day 1)

Reporting group description:

Treatment-naive participants with HIV-1 infection took MK-1439A, a single-tablet fixed dose combination (FDC) containing doravirine (DOR) 100 mg + lamivudine (3TC) 300 mg + tenofovir disoproxil fumarate (TDF) 300 mg, once daily (q.d.) by mouth for 96 weeks. Participants also took 1 placebo tablet matched to ATRIPLA™ q.d. by mouth for 96 weeks in order to maintain blinding. Eligible participants from the Base Study (Day 1 to Week 96) may have entered open-label optional study extensions to receive MK-1439A (FDC containing DOR 100 mg + 3TC 300 mg + TDF 300 mg), taken q.d. during Study Extension 1 (Weeks 96 to 192), Extension 2 (Weeks 192 to 288), and Extension 3 (Weeks 288 to 384).

Reporting group title	ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)

Reporting group description:

Treatment-naive participants with HIV-1 infection took ATRIPLA™, a single-tablet FDC containing efavirenz (EFV) 600 mg + emtricitabine (FTC) 200 mg + tenofovir disoproxil fumarate (TDF) 300 mg (equivalent to 245 mg tenofovir disoproxil), q.d. by mouth for 96 weeks. Participants also took 1 placebo tablet matched to MK-1439A q.d. by mouth for 96 weeks in order to maintain blinding. Eligible participants from the Base Study (Day 1 to Week 96) may have entered open-label optional study extensions to receive MK-1439A (FDC containing DOR 100 mg + 3TC 300 mg + TDF 300 mg), taken q.d. during Study Extension 1 (Weeks 96 to 192), Extension 2 (Weeks 192 to 288), and Extension 3

(Weeks 288 to 384).

Reporting group title	MK-1439A (DOR/3TC/TDF from Day 1)

Reporting group description:

Treatment-naive participants with HIV-1 infection took MK-1439A, a single-tablet fixed dose combination (FDC) containing doravirine (DOR) 100 mg + lamivudine (3TC) 300 mg + tenofovir disoproxil fumarate (TDF) 300 mg, once daily (q.d.) by mouth for 96 weeks. Participants also took 1 placebo tablet matched to ATRIPLA™ q.d. by mouth for 96 weeks in order to maintain blinding. Eligible participants from the Base Study (Day 1 to Week 96) may have entered open-label optional study extensions to receive MK-1439A (FDC containing DOR 100 mg + 3TC 300 mg + TDF 300 mg), taken q.d. during Study Extension 1 (Weeks 96 to 192), Extension 2 (Weeks 192 to 288), and Extension 3 (Weeks 288 to 384).

Reporting group title	ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)

Reporting group description:

Treatment-naive participants with HIV-1 infection took ATRIPLA™, a single-tablet FDC containing efavirenz (EFV) 600 mg + emtricitabine (FTC) 200 mg + tenofovir disoproxil fumarate (TDF) 300 mg (equivalent to 245 mg tenofovir disoproxil), q.d. by mouth for 96 weeks. Participants also took 1 placebo tablet matched to MK-1439A q.d. by mouth for 96 weeks in order to maintain blinding. Eligible participants from the Base Study (Day 1 to Week 96) may have entered open-label optional study extensions to receive MK-1439A (FDC containing DOR 100 mg + 3TC 300 mg + TDF 300 mg), taken q.d. during Study Extension 1 (Weeks 96 to 192), Extension 2 (Weeks 192 to 288), and Extension 3 (Weeks 288 to 384).

Primary: Percentage of participants with HIV-1 ribonucleic acid (RNA) <50 copies/mL at Week 48

End point title	Percentage of participants with HIV-1 ribonucleic acid (RNA) <50 copies/mL at Week 48

End point description:

The percentage of participants in each arm with HIV-1 RNA levels <50 copies/mL at Week 48 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach in which all missing data are considered treatment failures, regardless of the reason. The analysis population consists of all randomized participants who received ≥1 dose of study medication and had baseline HIV-1 RNA data available.

End point type	Primary

End point timeframe:

Week 48

End point values	MK-1439A (DOR/3TC/TDF from Day 1)	ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	364	364		
Units: Percentage of Participants				
number (not applicable)	84.3	80.8		

Statistical analyses

Statistical analysis title	Non-inferiority Analysis for MK-1439A

Statistical analysis description:

The 95% CIs for difference in percentages were calculated using stratum-adjusted Mantel-Haenszel

method for each stratum (HIV-1 RNA ≤100,000 or >100,000 copies/mL).

Comparison groups	MK-1439A (DOR/3TC/TDF from Day 1) v ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)
Number of subjects included in analysis	728
Analysis specification	Pre-specified
Analysis type	non-inferiority[1]
Parameter estimate	Difference in percentages
Point estimate	3.537
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.951
upper limit	9.026

Notes:

[1] - Non-inferiority was declared if the lower bound of the 95% CI of the mean treatment difference was greater than -10.

Primary: Percentage of participants with Tier-1 neuropsychiatric adverse events (AEs)

End point title	Percentage of participants with Tier-1 neuropsychiatric adverse events (AEs)

End point description:

The percentage of participants in each arm experiencing ≥1 pre-specified Tier-1 neuropsychiatric AEs was determined. The list of Tier-1 neuropsychiatric AE categories included "dizziness", "sleep disorders and disturbances", and "altered sensorium" (including disturbance in attention). The analysis population consists of all randomized participants who received ≥1 dose of study medication.

End point type	Primary

End point timeframe:

Up to Week 48

End point values	MK-1439A (DOR/3TC/TDF from Day 1)	ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	364	364		
Units: Percentage of Participants				
number (not applicable)				
Dizziness	8.8	37.1		
Sleep disorders and disturbances	12.1	25.5		
Altered sensorium	4.4	8.2		

Statistical analyses

Statistical analysis title	Superiority Analysis of neuropsychiatric AEs

Statistical analysis description:

The 95% CIs for difference (dizziness difference) in percentages were calculated Miettinen and Nurminen method.

Comparison groups	MK-1439A (DOR/3TC/TDF from Day 1) v ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)

Number of subjects included in analysis	728
Analysis specification	Pre-specified
Analysis type	superiority[2]
P-value	< 0.001 [3]
Method	t-test, 2-sided
Parameter estimate	Difference in percentages
Point estimate	-28.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-34
upper limit	-22.5

Notes:

[2] - Superiority was declared when the 1-sided p-value comparing treatment difference was <0.02497. 95% CIs were calculated using the Miettinen and Nurminen method.

[3] - 2-sided P-value

Statistical analysis title	Superiority Analysis of neuropsychiatric AE's

Statistical analysis description:

The 95% CIs for difference (sleep disorders and disturbances difference) in percentages were calculated Miettinen and Nurminen method.

Comparison groups	MK-1439A (DOR/3TC/TDF from Day 1) v ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)
Number of subjects included in analysis	728
Analysis specification	Pre-specified
Analysis type	superiority[4]
P-value	< 0.001 [5]
Method	t-test, 2-sided
Parameter estimate	Difference in percentages
Point estimate	-13.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-19.1
upper limit	-7.9

Notes:

[4] - Superiority was declared when the 1-sided p-value comparing treatment difference was <0.02497.

[5] - 2-sided P-value

Statistical analysis title	Superiority Analysis of neuropsychiatric AE's

Statistical analysis description:

The 95% CIs for difference (Altered sensorium difference) in percentages were calculated Miettinen and Nurminen method.

Comparison groups	MK-1439A (DOR/3TC/TDF from Day 1) v ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)
Number of subjects included in analysis	728
Analysis specification	Pre-specified
Analysis type	superiority[6]
P-value	= 0.033 [7]
Method	t-test, 2-sided
Parameter estimate	Difference in percentages
Point estimate	-3.8

Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.6
upper limit	-0.3

Notes:

[6] - Superiority was declared when the 1-sided p-value comparing treatment difference was <0.02497.

[7] - 2-sided P-value

Secondary: Percentage of participants with HIV-1 RNA <50 copies/mL at Week 96

End point title	Percentage of participants with HIV-1 RNA <50 copies/mL at Week 96

End point description:

The percentage of participants in each arm with HIV-1 RNA levels <50 copies/mL at Week 96 were be determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. The US Food and Drug Administration (FDA) "snapshot" approach (i.e., all missing data handled as treatment failures, regardless of the reason) were used for efficacy analyses. The analysis population consisted of all randomized participants who received ≥1 dose of study medication and had baseline HIV-1 RNA data available.

End point type	Secondary

End point timeframe:

Week 96

End point values	MK-1439A (DOR/3TC/TDF from Day 1)	ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	364	364		
Units: Percentage of participants				
number (confidence interval 95%)	77.5 (72.8 to 81.7)	73.6 (68.8 to 78.1)		

Statistical analyses

Statistical analysis title	Non-inferiority analysis for MK-1439A

Statistical analysis description:

The 95% CIs for the treatment differences in percent response were calculated using stratum-adjusted Mantel-Haenszel method with the difference weighted by the harmonic mean of sample size per arm for each stratum (HIV-1 RNA ≤100,000 or >100,000 copies/mL).

Comparison groups	MK-1439A (DOR/3TC/TDF from Day 1) v ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)
Number of subjects included in analysis	728
Analysis specification	Pre-specified
Analysis type	non-inferiority[8]
Parameter estimate	Difference in percentages
Point estimate	3.815

Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.412
upper limit	10.042

Notes:

[8] - Non-inferiority was declared if the lower bound of the 95% CI of the mean treatment difference was greater than -10.

Secondary: Percentage of participants with HIV-1 RNA <40 copies/mL at Week 48

End point title	Percentage of participants with HIV-1 RNA <40 copies/mL at Week 48

End point description:

The percentage of participants in each arm with HIV-1 RNA levels <40 copies/mL (including target detected and target not detected) at Week 48 was determined. Plasma HIV RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach in which all missing data are considered treatment failures, regardless of the reason. The analysis population consists of all randomized participants who received ≥1 dose of study medication and had baseline HIV-1 RNA data available.

End point type	Secondary

End point timeframe:

Week 48

End point values	MK-1439A (DOR/3TC/TDF from Day 1)	ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	364	364		
Units: Percentage of Participants				
number (confidence interval 95%)	83.8 (79.6 to 87.4)	79.7 (75.2 to 83.7)		

Statistical analyses

Statistical analysis title	Non-inferiority analysis for MK-1439A

Statistical analysis description:

The 95% CIs for difference in percentages were calculated using stratum-adjusted Mantel-Haenszel method for each stratum (HIV-1 RNA ≤100,000 or >100,000 copies/mL).

Comparison groups	MK-1439A (DOR/3TC/TDF from Day 1) v ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)
Number of subjects included in analysis	728
Analysis specification	Pre-specified
Analysis type	non-inferiority[9]
Parameter estimate	Difference in percentages
Point estimate	4.1

Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.5
upper limit	9.7

Notes:

[9] - Non-inferiority was declared if the lower bound of the 95% CI of the mean treatment difference was greater than -10.

Secondary: Change from baseline in CD4 cell counts at Week 48

End point title	Change from baseline in CD4 cell counts at Week 48

End point description:

The mean change from baseline in CD4 cell counts at Week 48 was assessed using the Observed Failure (OF) approach. With the OF approach, baseline values were carried forward for participants who discontinued prior to Week 48 due to lack of efficacy. Cell counts at Baseline and Week 48 were measured and expressed as cells/mm^3, and percent change was then calculated as [(Baseline counts - Week 48 counts)*100]. CD4 cell counts were quantified by a central laboratory using a commercially available assay. The analysis population consisted of all randomized participants who received ≥1 dose of study medication and had baseline and Week 48 CD4 data available.

End point type	Secondary

End point timeframe:

Baseline (Day 1) and Week 48

End point values	MK-1439A (DOR/3TC/TDF from Day 1)	ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	344	329		
Units: Percentage Change from Baseline				
arithmetic mean (confidence interval 95%)	198.4 (180.2 to 216.7)	188.4 (169.5 to 207.2)		

Statistical analyses

Statistical analysis title	Superiority analysis for MK-1439A

Statistical analysis description:

95% CIs were calculated based on t-distribution.

Comparison groups	MK-1439A (DOR/3TC/TDF from Day 1) v ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)
Number of subjects included in analysis	673
Analysis specification	Pre-specified
Analysis type	superiority[10]
Parameter estimate	Difference in mean %change from baseline
Point estimate	10.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.1
upper limit	36.3

Notes:

[10] - Superiority was declared when group difference (MK-1439A-ATRIPLA®) was a positive value.

Secondary: Percentage of participants with HIV-1 RNA <40 copies/mL at Week 96

End point title	Percentage of participants with HIV-1 RNA <40 copies/mL at Week 96

End point description:

The percentage of participants in each arm with HIV-1 RNA levels <40 copies/mL (including target detected and target not detected) at Week 96 were determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. The US Food and Drug Administration (FDA) "snapshot" approach (i.e., all missing data handled as treatment failures, regardless of the reason) were used for efficacy analyses. The analysis population consisted of all randomized participants who received ≥1 dose of study medication and had baseline HIV-1 RNA data available.

End point type	Secondary

End point timeframe:

Week 96

End point values	MK-1439A (DOR/3TC/TDF from Day 1)	ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	364	364		
Units: Percentage of participants				
number (confidence interval 95%)	76.1 (71.4 to 80.4)	72.8 (67.9 to 77.3)		

Statistical analyses

Statistical analysis title	Non-inferiority analysis for MK-1439A

Statistical analysis description:

The 95% CIs for the treatment differences in percent response were calculated using stratum-adjusted Mantel-Haenszel method with the difference weighted by the harmonic mean of sample size per arm for each stratum (HIV-1 RNA ≤100,000 or >100,000 copies/mL).

Comparison groups	MK-1439A (DOR/3TC/TDF from Day 1) v ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)
Number of subjects included in analysis	728
Analysis specification	Pre-specified
Analysis type	non-inferiority[11]
Parameter estimate	Difference in percentages
Point estimate	3.268
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.057
upper limit	9.593

Notes:

[11] - Non-inferiority was declared if the lower bound of the 95% CI of the mean treatment difference was greater than -10.

Secondary: Change from baseline in CD4 cell counts at Week 96

End point title	Change from baseline in CD4 cell counts at Week 96

End point description:

The mean change from baseline in CD4 cell counts at Week 96 was assessed using the OF approach. With the OF approach, baseline values were carried forward for participants who discontinued prior to Week 96 due to lack of efficacy. Cell counts at Baseline and Week 96 were measured and expressed as cells/mm^3, and percent change was calculated as [(Baseline counts - Week 96 counts)*100]. CD4 cell counts were quantified by a central laboratory using a commercially available assay. The analysis population consisted of all randomized participants who received ≥1 dose of study medication and had baseline and week 96 CD4 data available.

End point type	Secondary

End point timeframe:

Baseline (Day 1) and Week 96

End point values	MK-1439A (DOR/3TC/TDF from Day 1)	ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	337	311		
Units: Percentage Change from Baseline				
arithmetic mean (confidence interval 95%)	237.7 (214.9 to 260.6)	223.0 (198.4 to 247.6)		

Statistical analyses

Statistical analysis title	Superiority analysis for MK-1439A

Statistical analysis description:

The 95% CIs were calculated based on t-distribution.

Comparison groups	MK-1439A (DOR/3TC/TDF from Day 1) v ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)
Number of subjects included in analysis	648
Analysis specification	Pre-specified
Analysis type	superiority[12]
Parameter estimate	Diff in mean % change from baseline
Point estimate	14.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-18.7
upper limit	48.2

Notes:

[12] - Superiority was declared when group difference (MK-1439A-ATRIPLA) was a positive value.

Secondary: Percentage of participants discontinuing from study medication due to an AE(s)

End point title	Percentage of participants discontinuing from study medication due to an AE(s)

End point description:

An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The analysis population consisted of all randomized participants who received ≥1 dose of study medication.

End point type	Secondary

End point timeframe:

Up to Week 48

End point values	MK-1439A (DOR/3TC/TDF from Day 1)	ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	364	364		
Units: Percentage of participants				
number (not applicable)	3.0	6.6		

Statistical analyses

Statistical analysis title	Diff in % analysis in participant discontinuation
Comparison groups	MK-1439A (DOR/3TC/TDF from Day 1) v ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)
Number of subjects included in analysis	728
Analysis specification	Pre-specified
Analysis type	other[13]
Parameter estimate	Difference in percentages
Point estimate	-3.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.9
upper limit	-0.5

Notes:

[13] - Difference in percentage of participants with ≥1 AE(s)

Secondary: Percentage of participants experiencing ≥1 AE

End point title	Percentage of participants experiencing ≥1 AE

End point description:

An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The analysis population consisted of all randomized participants who received ≥1 dose of study medication.

End point type	Secondary

End point timeframe:

Up to Week 48

End point values	MK-1439A (DOR/3TC/TDF from Day 1)	ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	364	364		
Units: Percentage of participants				
number (not applicable)	82.7	90.7		

Statistical analyses

Statistical analysis title	Diff in % analysis vs. ATRIPLA™
Comparison groups	MK-1439A (DOR/3TC/TDF from Day 1) v ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)
Number of subjects included in analysis	728
Analysis specification	Pre-specified
Analysis type	other[14]
Parameter estimate	Difference in percentages
Point estimate	-8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13
upper limit	-3.1

Notes:

[14] - Difference in percentage of participants with ≥1 AE(s)

Secondary: Percentage of participants with Tier-2 neuropsychiatric AEs

End point title	Percentage of participants with Tier-2 neuropsychiatric AEs

End point description:

The percentage of participants in each arm experiencing ≥1 pre-specified Tier-2 neuropsychiatric AEs was determined. The list of Tier-2 neuropsychiatric AE categories included "depression and suicide/self-injury" and "psychosis and psychotic disorders". The analysis population consists of all randomized participants who received ≥1 dose of study medication.

End point type	Secondary

End point timeframe:

Up to Week 48

End point values	MK-1439A (DOR/3TC/TDF from Day 1)	ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	364	364		
Units: Percentage of Participants				
number (not applicable)				
Depression and suicide/self-injury	4.1	6.6		
Psychosis and psychotic disorders	0.3	1.1		

Statistical analyses

Statistical analysis title	% analysis of neuropsychiatric AEs in participants
Statistical analysis description:	
Psychosis and psychotic disorders difference	
Comparison groups	MK-1439A (DOR/3TC/TDF from Day 1) v ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)
Number of subjects included in analysis	728
Analysis specification	Pre-specified
Analysis type	other[15]
P-value	< 0.001 [16]
Method	t-test, 2-sided
Parameter estimate	Difference in percentages
Point estimate	-0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.5
upper limit	0.5

Notes:

[15] - Superiority was declared when the 1-sided p-value comparing treatment difference was <0. 02497. 95% CIs were calculated using the Miettinen and Nurminen method.
[16] - 2-sided P-value

Statistical analysis title	% analysis of neuropsychiatric AEs in participants
Statistical analysis description:	
Depression and suicide/self-injury difference	
Comparison groups	MK-1439A (DOR/3TC/TDF from Day 1) v ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)
Number of subjects included in analysis	728
Analysis specification	Pre-specified
Analysis type	other[17]
P-value	< 0.001 [18]
Method	t-test, 2-sided
Parameter estimate	Difference in percentages
Point estimate	-2.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.9
upper limit	0.8

Notes:

[17] - Superiority was declared when the 1-sided p-value comparing treatment difference was <0. 02497. 95% CIs were calculated using the Miettinen and Nurminen method.
[18] - 2-sided P-value

Secondary: Change from baseline in fasting LDL-C at Week 48

End point title	Change from baseline in fasting LDL-C at Week 48

End point description:

The mean percent change from baseline in fasting (fast duration of ≥8 hours) LDL-C levels at Week 48 was determined for each arm. The Last Observation Carry Forward (LOCF) approach was applied to missing data and data collected after a participant-initiated lipid-modifying therapy. The analysis population consists of all randomized participants who had baseline LDL-C data available as well as ≥1 LDL-C measurement after initiating study treatment.

End point type	Secondary

End point timeframe:

Baseline (Day 1) and Week 48

End point values	MK-1439A (DOR/3TC/TDF from Day 1)	ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	330	305		
Units: Percent Change from Baseline				
arithmetic mean (confidence interval 95%)	-1.58 (-3.98 to 0.81)	8.74 (5.86 to 11.62)		

Statistical analyses

Statistical analysis title	% change from baseline in LDL-C

Statistical analysis description:

95% CIs and 2-sided p-values for treatment difference were calculated from an ANCOVA model with terms for baseline lipid level and treatment.

Comparison groups	MK-1439A (DOR/3TC/TDF from Day 1) v ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)
Number of subjects included in analysis	635
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.0001
Method	ANCOVA
Parameter estimate	Difference in mean %change from baseline
Point estimate	-10.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.53
upper limit	-6.49

Secondary: Change from baseline in fasting non-HDL-C at Week 48

End point title	Change from baseline in fasting non-HDL-C at Week 48

End point description:

The mean percent change from baseline in fasting (fast duration of ≥8 hours) non-HDL-C levels at Week 48 was determined for each arm. The LOCF approach was applied to missing data and data collected

after a participant initiated lipid-modifying therapy. The analysis population consists of all randomized participants who had baseline non-HDL-C data available as well as ≥1 non-HDL-C measurement after initiating study treatment.

End point type	Secondary

End point timeframe:

Baseline (Day 1) and Week 48

End point values	MK-1439A (DOR/3TC/TDF from Day 1)	ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	333	314		
Units: Percent Change from Baseline				
arithmetic mean (confidence interval 95%)	-3.83 (-6.27 to -1.40)	13.26 (10.07 to 16.45)		

Statistical analyses

Statistical analysis title	% change from baseline in non-HDL-C

Statistical analysis description:

95% CIs and 2-sided p-values for treatment difference were calculated from an ANCOVA model with terms for baseline lipid level and treatment.

Comparison groups	MK-1439A (DOR/3TC/TDF from Day 1) v ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)
Number of subjects included in analysis	647
Analysis specification	Pre-specified
Analysis type	other
P-value	< 0.0001
Method	ANCOVA
Parameter estimate	Difference in mean %change from baseline
Point estimate	-17.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	-20.89
upper limit	-13.16

Secondary: Change from baseline in fasting cholesterol at Week 48

End point title	Change from baseline in fasting cholesterol at Week 48

End point description:

The mean percent change from baseline in fasting (fast duration of ≥8 hours) cholesterol levels at Week 48 was determined for each arm. The LOCF approach was applied to missing data and data collected after a participant-initiated lipid-modifying therapy. The analysis population consists of all randomized participants who had baseline cholesterol data available as well as ≥1 cholesterol measurement after initiating study treatment.

End point type	Secondary

End point timeframe:

Baseline (Day 1) and Week 48

End point values	MK-1439A (DOR/3TC/TDF from Day 1)	ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	333	314		
Units: Percent Change from Baseline				
arithmetic mean (confidence interval 95%)	-1.97 (-4.74 to 0.79)	21.77 (18.35 to 25.18)		

Statistical analyses

Statistical analysis title	% change from baseline in fasting cholesterol

Statistical analysis description:

95% CIs for treatment difference were calculated from an ANCOVA model with terms for baseline lipid level and treatment.

Comparison groups	MK-1439A (DOR/3TC/TDF from Day 1) v ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)
Number of subjects included in analysis	647
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Difference in mean %change from baseline
Point estimate	-23.44
Confidence interval	
level	95 %
sides	2-sided
lower limit	-27.57
upper limit	-19.32

Secondary: Change from baseline in fasting triglycerides at Week 48

End point title	Change from baseline in fasting triglycerides at Week 48

End point description:

The mean percent change from baseline in fasting (fast duration of ≥8 hours) triglycerides levels at Week 48 was determined for each arm. The LOCF approach was applied to missing data and data collected after a participant initiated lipid-modifying therapy. The analysis population consists of all randomized participants who had baseline triglyceride data available as well as ≥1 triglyceride measurement after initiating study treatment.

End point type	Secondary

End point timeframe:

Baseline (Day 1) and Week 48

End point values	MK-1439A (DOR/3TC/TDF from Day 1)	ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	333	314		
Units: Percent Change from Baseline				
arithmetic mean (confidence interval 95%)	-12.40 (-19.66 to -5.15)	22.01 (11.68 to 32.34)		

Statistical analyses

Statistical analysis title	% change from baseline in fasting triglycerides
Statistical analysis description:	
95% CIs for treatment difference were calculated from an ANCOVA model with terms for baseline lipid level and treatment.	
Comparison groups	MK-1439A (DOR/3TC/TDF from Day 1) v ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)
Number of subjects included in analysis	647
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Difference in mean %change from baseline
Point estimate	-35.96
Confidence interval	
level	95 %
sides	2-sided
lower limit	-47.1
upper limit	-24.82

Secondary: Change from baseline in fasting HDL-C at Week 48

End point title	Change from baseline in fasting HDL-C at Week 48
End point description:	
The mean percent change from baseline in fasting (fast duration of ≥8 hours) HDL-C levels at Week 48 was determined for each arm. The LOCF approach was applied to missing data and data collected after a participant-initiated lipid-modifying therapy. The analysis population consists of all randomized participants who had baseline HDL-C data available as well as ≥1 HDL-C measurement after initiating study treatment.	
End point type	Secondary
End point timeframe:	
Baseline (Day 1) and Week 48	

End point values	MK-1439A (DOR/3TC/TDF from Day 1)	ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	333	314		
Units: Percent Change from Baseline				
arithmetic mean (confidence interval 95%)	1.86 (0.83 to 2.89)	8.51 (7.32 to 9.69)		

Statistical analyses

Statistical analysis title	% change from baseline in fasting HDL-C
Statistical analysis description:	
95% CIs for treatment difference were calculated from an ANCOVA model with terms for baseline lipid level and treatment.	
Comparison groups	MK-1439A (DOR/3TC/TDF from Day 1) v ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)
Number of subjects included in analysis	647
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Difference in mean %change from baseline
Point estimate	-6.47
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.97
upper limit	-4.96

Secondary: Percentage of participants with HIV-1 RNA below the limit of quantification (BLoQ) at Week 48

End point title	Percentage of participants with HIV-1 RNA below the limit of quantification (BLoQ) at Week 48
End point description:	
The percentage of participants in each arm with HIV-1 RNA levels BLoQ of 40 copies/mL and target not detected at Week 48 was determined. Plasma HIV RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled as observed. The analysis population consists of all randomized participants who received ≥1 dose of study medication and had baseline HIV-1 RNA data available.	
End point type	Secondary
End point timeframe:	
Week 48	

End point values	MK-1439A (DOR/3TC/TDF from Day 1)	ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	364	364		
Units: Percentage of Participants				
number (not applicable)	59.6	55.5		

Statistical analyses

No statistical analyses for this end point

Secondary: Plasma concentration of doravirine at Week 48

End point title	Plasma concentration of doravirine at Week 48[19]

End point description:

Plasma samples were collected for analysis of doravirine concentration at Week 48. A total of 2 samples were collected: 1 prior to dosing and 1 collected between 0.5 and 2 hours post-dose. The analysis population consists of all randomized participants in the MK-1439A arm who received ≥1 dose of study drug and had doravirine concentration data available.

End point type	Secondary

End point timeframe:

0 hours post-dose and 2 hours post-dose on Week 48

Notes:

[19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: plasma concentrations from this trial were included in this population PK analysis of pooled phase data.

End point values	MK-1439A (DOR/3TC/TDF from Day 1)			
Subject group type	Reporting group			
Number of subjects analysed	312			
Units: nM				
arithmetic mean (standard deviation)				
Pre-dose	1290 (± 799)			
0.5 to 2 hours post-dose	2330 (± 1230)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with HIV-1 RNA BLoQ at Week 96

End point title	Percentage of participants with HIV-1 RNA BLoQ at Week 96

End point description:

The percentage of participants in each arm with HIV-1 RNA levels BLoQ of 40 copies/mL and target not detected at Week 96 were determined. Plasma HIV RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled as observed. The analysis population consisted of all randomized participants who received ≥1 dose of study medication and had baseline HIV-1 RNA data available.

End point type	Secondary

End point timeframe:

Week 96

End point values	MK-1439A (DOR/3TC/TDF from Day 1)	ATRIPLA™ (Switch from EFV/FTC/TDF at Week 96)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	364	364		
Units: Percentage of Participants				
number (not applicable)	59.3	59.1		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to 96 weeks

Adverse event reporting additional description:

All cause-mortality: all allocated participants. Serious and non-serious AEs: all allocated participants who received ≥1 dose of study treatment. Per protocol, non-serious adverse event data were not collected during Study Extensions 2 and 3.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	23.0

Reporting groups

Reporting group title	DOR/3TC/TDF Only (from Day 1) at Base Study

Reporting group description:

Treatment-naive participants took a single-tablet FDC containing doravirine 100 mg + lamivudine 300 mg + tenofovir disoproxil fumarate 300 mg, q.d. by mouth for a total of 96 weeks.

Reporting group title	DOR/3TC/TDF Switch at Week 96 Base Study

Reporting group description:

Treatment-naive participants with HIV-1 infection took ATRIPLA™, a single-tablet FDC containing efavirenz 600 mg + emtricitabine 200 mg + tenofovir disoproxil fumarate 300 mg (equivalent to 245 mg tenofovir disoproxil), q.d. by mouth for 48 weeks (and will take ATRIPLA for an additional 48 weeks for a total of 96 weeks).

Reporting group title	DOR/3TC/TDF Only (DOR/3TC/TDF from Day 1) Ext 1

Reporting group description:

One doravirine, tenofovir, lamivudine taken q.d. by mouth for an additional 96 weeks (Week 96 - Week 192)

Reporting group title	DOR/3TC/TDF Switch (Switch from EFV/FTC/TDF at Week 96) Ext 1

Reporting group description:

One doravirine, tenofovir, lamivudine taken q.d. by mouth for an additional 96 weeks (Week 96 - Week 192)

Reporting group title	DOR/3TC/TDF Only (DOR/3TC/TDF from Day 1) Ext 2

Reporting group description:

One doravirine, tenofovir, lamivudine taken q.d. by mouth for an additional 96 weeks (Week 192 - Week 288)

Reporting group title	DOR/3TC/TDF Switch (Switch from EFV/FTC/TDF at Week 96) Ext 2

Reporting group description:

One doravirine, tenofovir, lamivudine taken q.d. by mouth for an additional 96 weeks (Week 192 - Week 288)

Reporting group title	DOR/3TC/TDF Only (DOR/3TC/TDF from Day 1) Ext 3

Reporting group description:

One doravirine, tenofovir, lamivudine taken q.d. by mouth for an additional 96 weeks (Week 388 - Week 384)

Reporting group title	DOR/3TC/TDF Switch (Switch from EFV/FTC/TDF at Week 96) Ext 3

Reporting group description:

One doravirine, tenofovir, lamivudine taken q.d. by mouth for an additional 96 weeks (Week 388 - Week 384)

Serious adverse events	DOR/3TC/TDF Only (from Day 1) at Base Study	DOR/3TC/TDF Switch at Week 96 Base Study	DOR/3TC/TDF Only (DOR/3TC/TDF from Day 1) Ext 1
Total subjects affected by serious adverse events			
subjects affected / exposed	22 / 364 (6.04%)	30 / 364 (8.24%)	19 / 291 (6.53%)
number of deaths (all causes)	1	4	2
number of deaths resulting from adverse events	0	2	1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Anal squamous cell carcinoma			
subjects affected / exposed	1 / 364 (0.27%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anogenital warts			
subjects affected / exposed	2 / 364 (0.55%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Basal cell carcinoma			
subjects affected / exposed	0 / 364 (0.00%)	2 / 364 (0.55%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Kaposi's sarcoma			
subjects affected / exposed	0 / 364 (0.00%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurofibroma			
subjects affected / exposed	0 / 364 (0.00%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of the tongue			
subjects affected / exposed	1 / 364 (0.27%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leiomyosarcoma metastatic			

subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	1 / 291 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Meningioma			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	1 / 291 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hodgkin's disease			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostate cancer			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaplastic large-cell lymphoma			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Malignant hypertension			
subjects affected / exposed	0 / 364 (0.00%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	1 / 364 (0.27%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Ectopic pregnancy			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	1 / 291 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Death			
subjects affected / exposed	0 / 364 (0.00%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Asthenia			
subjects affected / exposed	1 / 364 (0.27%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inflammation			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Gynaecomastia			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 364 (0.00%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleuritic pain			

subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	1 / 291 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Completed suicide			
subjects affected / exposed	0 / 364 (0.00%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Insomnia			
subjects affected / exposed	1 / 364 (0.27%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nightmare			
subjects affected / exposed	1 / 364 (0.27%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			
subjects affected / exposed	0 / 364 (0.00%)	1 / 364 (0.27%)	1 / 291 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Schizophrenia			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	1 / 291 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Alcohol poisoning			

subjects affected / exposed	0 / 364 (0.00%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ankle fracture			
subjects affected / exposed	0 / 364 (0.00%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haemorrhage			
subjects affected / exposed	1 / 364 (0.27%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma			
subjects affected / exposed	0 / 364 (0.00%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Traumatic haemothorax			
subjects affected / exposed	1 / 364 (0.27%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Accidental overdose			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	1 / 291 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acetabulum fracture			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot fracture			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wrist fracture			

subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple injuries			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	2 / 291 (0.69%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Craniocerebral injury			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Road traffic accident			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Poisoning			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Limb injury			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Facial bones fracture			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Phimosis			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			

Supraventricular tachycardia			
subjects affected / exposed	1 / 364 (0.27%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tachycardia			
subjects affected / exposed	1 / 364 (0.27%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	1 / 291 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arrhythmia			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myopericarditis			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Seizure			
subjects affected / exposed	1 / 364 (0.27%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 364 (0.00%)	1 / 364 (0.27%)	1 / 291 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Normocytic anaemia			
subjects affected / exposed	1 / 364 (0.27%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Anaemia			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	1 / 291 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Colitis			
subjects affected / exposed	0 / 364 (0.00%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal obstruction			
subjects affected / exposed	1 / 364 (0.27%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	1 / 291 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incarcerated umbilical hernia			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Proctitis ulcerative			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	1 / 291 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis ulcerative			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			

Bile duct stone			
subjects affected / exposed	1 / 364 (0.27%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertransaminasaemia			
subjects affected / exposed	1 / 364 (0.27%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangitis			
subjects affected / exposed	1 / 364 (0.27%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Lipodystrophy acquired			
subjects affected / exposed	1 / 364 (0.27%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psoriasis			
subjects affected / exposed	1 / 364 (0.27%)	0 / 364 (0.00%)	1 / 291 (0.34%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash maculo-papular			
subjects affected / exposed	0 / 364 (0.00%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash macular			
subjects affected / exposed	0 / 364 (0.00%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash			

subjects affected / exposed	0 / 364 (0.00%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 364 (0.00%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrotic syndrome			
subjects affected / exposed	0 / 364 (0.00%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mania			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Thyroid cyst			
subjects affected / exposed	0 / 364 (0.00%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxic nodular goitre			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Muscle spasms			
subjects affected / exposed	0 / 364 (0.00%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Rhabdomyolysis			
subjects affected / exposed	0 / 364 (0.00%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vertebral foraminal stenosis			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	1 / 291 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Anal infection			
subjects affected / exposed	1 / 364 (0.27%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess limb			
subjects affected / exposed	1 / 364 (0.27%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	1 / 364 (0.27%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	1 / 364 (0.27%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	0 / 364 (0.00%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endometritis			
subjects affected / exposed	1 / 364 (0.27%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epididymitis			

subjects affected / exposed	0 / 364 (0.00%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis A			
subjects affected / exposed	1 / 364 (0.27%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal viral infection			
subjects affected / exposed	0 / 364 (0.00%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine infection			
subjects affected / exposed	0 / 364 (0.00%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenitis bacterial			
subjects affected / exposed	0 / 364 (0.00%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nasopharyngitis			
subjects affected / exposed	1 / 364 (0.27%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oophoritis			
subjects affected / exposed	0 / 364 (0.00%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral bacterial infection			
subjects affected / exposed	0 / 364 (0.00%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pilonidal disease			

subjects affected / exposed	0 / 364 (0.00%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	2 / 364 (0.55%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial			
subjects affected / exposed	0 / 364 (0.00%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus infection			
subjects affected / exposed	0 / 364 (0.00%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 364 (0.00%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	1 / 364 (0.27%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal abscess			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	1 / 291 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial infection			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia			

subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	1 / 291 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea infectious			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	1 / 291 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orchitis mumps			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	1 / 291 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	1 / 291 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute hepatitis C			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurosyphilis			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile colitis			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			

subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus colitis			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 364 (0.00%)	0 / 364 (0.00%)	1 / 291 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hypertriglyceridaemia			
subjects affected / exposed	0 / 364 (0.00%)	1 / 364 (0.27%)	0 / 291 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	DOR/3TC/TDF Switch (Switch from EFV/FTC/TDF at Week 96) Ext 1	DOR/3TC/TDF Only (DOR/3TC/TDF from Day 1) Ext 2	DOR/3TC/TDF Switch (Switch from EFV/FTC/TDF at Week 96) Ext 2
Total subjects affected by serious adverse events			
subjects affected / exposed	12 / 269 (4.46%)	8 / 192 (4.17%)	9 / 173 (5.20%)
number of deaths (all causes)	0	2	2
number of deaths resulting from adverse events	0	0	2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Anal squamous cell carcinoma			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anogenital warts			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Basal cell carcinoma			

subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Kaposi's sarcoma			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurofibroma			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of the tongue			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leiomyosarcoma metastatic			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningioma			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hodgkin's disease			
subjects affected / exposed	0 / 269 (0.00%)	1 / 192 (0.52%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostate cancer			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaplastic large-cell lymphoma			

subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Malignant hypertension			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	1 / 173 (0.58%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ectopic pregnancy			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Death			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthenia			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			

subjects affected / exposed	0 / 269 (0.00%)	1 / 192 (0.52%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inflammation			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Gynaecomastia			
subjects affected / exposed	1 / 269 (0.37%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleuritic pain			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Completed suicide			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Insomnia			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nightmare			

subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Schizophrenia			
subjects affected / exposed	1 / 269 (0.37%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Alcohol poisoning			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ankle fracture			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haemorrhage			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Traumatic haemothorax			
subjects affected / exposed	0 / 269 (0.00%)	1 / 192 (0.52%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Accidental overdose			
subjects affected / exposed	1 / 269 (0.37%)	0 / 192 (0.00%)	1 / 173 (0.58%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acetabulum fracture			
subjects affected / exposed	1 / 269 (0.37%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot fracture			
subjects affected / exposed	1 / 269 (0.37%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wrist fracture			
subjects affected / exposed	1 / 269 (0.37%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple injuries			
subjects affected / exposed	1 / 269 (0.37%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Craniocerebral injury			
subjects affected / exposed	0 / 269 (0.00%)	1 / 192 (0.52%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Road traffic accident			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	1 / 173 (0.58%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Poisoning			

subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	1 / 173 (0.58%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Limb injury			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Facial bones fracture			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Phimosis			
subjects affected / exposed	1 / 269 (0.37%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Supraventricular tachycardia			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tachycardia			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arrhythmia			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	1 / 173 (0.58%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1

Myopericarditis			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Seizure			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Normocytic anaemia			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Colitis			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal obstruction			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			

subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incarcerated umbilical hernia			
subjects affected / exposed	1 / 269 (0.37%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Proctitis ulcerative			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis ulcerative			
subjects affected / exposed	0 / 269 (0.00%)	1 / 192 (0.52%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 269 (0.00%)	1 / 192 (0.52%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Bile duct stone			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertransaminasaemia			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangitis			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis			

subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Lipodystrophy acquired			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psoriasis			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash maculo-papular			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash macular			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrotic syndrome			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			

subjects affected / exposed	2 / 269 (0.74%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mania			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	1 / 173 (0.58%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Thyroid cyst			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxic nodular goitre			
subjects affected / exposed	1 / 269 (0.37%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Muscle spasms			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhabdomyolysis			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vertebral foraminal stenosis			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Anal infection			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Abscess limb			
subjects affected / exposed	0 / 269 (0.00%)	1 / 192 (0.52%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	1 / 269 (0.37%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endometritis			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epididymitis			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis A			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal viral infection			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine infection			

subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenitis bacterial			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nasopharyngitis			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	1 / 173 (0.58%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oophoritis			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral bacterial infection			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pilonidal disease			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus infection			

subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal abscess			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial infection			
subjects affected / exposed	1 / 269 (0.37%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	1 / 173 (0.58%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea infectious			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orchitis mumps			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis			

subjects affected / exposed	1 / 269 (0.37%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute hepatitis C			
subjects affected / exposed	0 / 269 (0.00%)	1 / 192 (0.52%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurosyphilis			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	1 / 173 (0.58%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile colitis			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus colitis			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hypertriglyceridaemia			

subjects affected / exposed	0 / 269 (0.00%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	DOR/3TC/TDF Only (DOR/3TC/TDF from Day 1) Ext 3	DOR/3TC/TDF Switch (Switch from EFV/FTC/TDF at Week 96) Ext 3	
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 121 (1.65%)	7 / 111 (6.31%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Anal squamous cell carcinoma			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anogenital warts			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal cell carcinoma			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Kaposi's sarcoma			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neurofibroma			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of the tongue			

subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leiomyosarcoma metastatic			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningioma			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hodgkin's disease			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer			
subjects affected / exposed	1 / 121 (0.83%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaplastic large-cell lymphoma			
subjects affected / exposed	0 / 121 (0.00%)	1 / 111 (0.90%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Malignant hypertension			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			
subjects affected / exposed	1 / 121 (0.83%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pregnancy, puerperium and perinatal conditions			

Abortion spontaneous			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ectopic pregnancy			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Death			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthenia			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inflammation			
subjects affected / exposed	0 / 121 (0.00%)	1 / 111 (0.90%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Gynaecomastia			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Asthma			

subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleuritic pain			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Completed suicide			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Insomnia			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nightmare			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicide attempt			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Schizophrenia			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Injury, poisoning and procedural complications			
Alcohol poisoning			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ankle fracture			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haemorrhage			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haematoma			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic haemothorax			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Accidental overdose			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acetabulum fracture			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot fracture			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Wrist fracture			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple injuries			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Craniocerebral injury			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Road traffic accident			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Poisoning			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb injury			
subjects affected / exposed	0 / 121 (0.00%)	1 / 111 (0.90%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial bones fracture			
subjects affected / exposed	0 / 121 (0.00%)	1 / 111 (0.90%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital, familial and genetic disorders			
Phimosis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Cardiac disorders			
Supraventricular tachycardia			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachycardia			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial infarction			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arrhythmia			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myopericarditis			
subjects affected / exposed	0 / 121 (0.00%)	1 / 111 (0.90%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Seizure			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Normocytic anaemia			

subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Colitis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal obstruction			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis acute			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incarcerated umbilical hernia			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Proctitis ulcerative			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis ulcerative			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			

subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Bile duct stone			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertransaminasaemia			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis			
subjects affected / exposed	1 / 121 (0.83%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Lipodystrophy acquired			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psoriasis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rash maculo-papular			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rash macular			

subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rash			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrotic syndrome			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrolithiasis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mania			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Thyroid cyst			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxic nodular goitre			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue			

disorders			
Muscle spasms			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhabdomyolysis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebral foraminal stenosis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Anal infection			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess limb			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis			
subjects affected / exposed	0 / 121 (0.00%)	1 / 111 (0.90%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile infection			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Endometritis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epididymitis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis A			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal viral infection			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine infection			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenitis bacterial			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasopharyngitis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oophoritis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oral bacterial infection			

subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pilonidal disease			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia bacterial			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory syncytial virus infection			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	0 / 121 (0.00%)	1 / 111 (0.90%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral infection			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal abscess			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial infection			

subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
COVID-19 pneumonia			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea infectious			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orchitis mumps			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonsillitis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonitis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute hepatitis C			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neurosyphilis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile colitis			

subjects affected / exposed	0 / 121 (0.00%)	1 / 111 (0.90%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
COVID-19			
subjects affected / exposed	0 / 121 (0.00%)	2 / 111 (1.80%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cytomegalovirus colitis			
subjects affected / exposed	0 / 121 (0.00%)	1 / 111 (0.90%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Hypertriglyceridaemia			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	DOR/3TC/TDF Only (from Day 1) at Base Study	DOR/3TC/TDF Switch at Week 96 Base Study	DOR/3TC/TDF Only (DOR/3TC/TDF from Day 1) Ext 1
Total subjects affected by non-serious adverse events			
subjects affected / exposed	231 / 364 (63.46%)	281 / 364 (77.20%)	111 / 291 (38.14%)
Nervous system disorders			
Dizziness			
subjects affected / exposed	37 / 364 (10.16%)	139 / 364 (38.19%)	2 / 291 (0.69%)
occurrences (all)	47	155	2
Headache			
subjects affected / exposed	58 / 364 (15.93%)	56 / 364 (15.38%)	18 / 291 (6.19%)
occurrences (all)	96	77	19
Somnolence			

subjects affected / exposed	13 / 364 (3.57%)	28 / 364 (7.69%)	2 / 291 (0.69%)
occurrences (all)	13	28	2
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	22 / 364 (6.04%)	24 / 364 (6.59%)	4 / 291 (1.37%)
occurrences (all)	25	26	4
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	50 / 364 (13.74%)	58 / 364 (15.93%)	16 / 291 (5.50%)
occurrences (all)	73	68	21
Nausea			
subjects affected / exposed	31 / 364 (8.52%)	42 / 364 (11.54%)	5 / 291 (1.72%)
occurrences (all)	35	55	5
Vomiting			
subjects affected / exposed	19 / 364 (5.22%)	29 / 364 (7.97%)	1 / 291 (0.34%)
occurrences (all)	23	42	3
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	22 / 364 (6.04%)	20 / 364 (5.49%)	8 / 291 (2.75%)
occurrences (all)	25	24	8
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	20 / 364 (5.49%)	50 / 364 (13.74%)	8 / 291 (2.75%)
occurrences (all)	22	54	9
Psychiatric disorders			
Abnormal dreams			
subjects affected / exposed	18 / 364 (4.95%)	44 / 364 (12.09%)	0 / 291 (0.00%)
occurrences (all)	20	49	0
Insomnia			
subjects affected / exposed	24 / 364 (6.59%)	38 / 364 (10.44%)	6 / 291 (2.06%)
occurrences (all)	35	42	7
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	18 / 364 (4.95%)	19 / 364 (5.22%)	7 / 291 (2.41%)
occurrences (all)	23	21	7
Infections and infestations			

Nasopharyngitis			
subjects affected / exposed	50 / 364 (13.74%)	43 / 364 (11.81%)	40 / 291 (13.75%)
occurrences (all)	89	61	58
Upper respiratory tract infection			
subjects affected / exposed	41 / 364 (11.26%)	30 / 364 (8.24%)	21 / 291 (7.22%)
occurrences (all)	55	40	33
Pharyngitis			
subjects affected / exposed	30 / 364 (8.24%)	20 / 364 (5.49%)	13 / 291 (4.47%)
occurrences (all)	39	27	16
Syphilis			
subjects affected / exposed	18 / 364 (4.95%)	14 / 364 (3.85%)	16 / 291 (5.50%)
occurrences (all)	21	15	18

Non-serious adverse events	DOR/3TC/TDF Switch (Switch from EFV/FTC/TDF at Week 96) Ext 1	DOR/3TC/TDF Only (DOR/3TC/TDF from Day 1) Ext 2	DOR/3TC/TDF Switch (Switch from EFV/FTC/TDF at Week 96) Ext 2
Total subjects affected by non-serious adverse events			
subjects affected / exposed	110 / 269 (40.89%)	0 / 192 (0.00%)	0 / 173 (0.00%)
Nervous system disorders			
Dizziness			
subjects affected / exposed	4 / 269 (1.49%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences (all)	4	0	0
Headache			
subjects affected / exposed	16 / 269 (5.95%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences (all)	21	0	0
Somnolence			
subjects affected / exposed	2 / 269 (0.74%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences (all)	2	0	0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	5 / 269 (1.86%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences (all)	5	0	0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	17 / 269 (6.32%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences (all)	18	0	0
Nausea			

subjects affected / exposed	7 / 269 (2.60%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences (all)	8	0	0
Vomiting			
subjects affected / exposed	4 / 269 (1.49%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences (all)	4	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	11 / 269 (4.09%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences (all)	12	0	0
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	5 / 269 (1.86%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences (all)	5	0	0
Psychiatric disorders			
Abnormal dreams			
subjects affected / exposed	2 / 269 (0.74%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences (all)	2	0	0
Insomnia			
subjects affected / exposed	10 / 269 (3.72%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences (all)	10	0	0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	14 / 269 (5.20%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences (all)	15	0	0
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	26 / 269 (9.67%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences (all)	36	0	0
Upper respiratory tract infection			
subjects affected / exposed	19 / 269 (7.06%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences (all)	22	0	0
Pharyngitis			
subjects affected / exposed	11 / 269 (4.09%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences (all)	18	0	0
Syphilis			

subjects affected / exposed	15 / 269 (5.58%)	0 / 192 (0.00%)	0 / 173 (0.00%)
occurrences (all)	17	0	0

Non-serious adverse events	DOR/3TC/TDF Only (DOR/3TC/TDF from Day 1) Ext 3	DOR/3TC/TDF Switch (Switch from EFV/FTC/TDF at Week 96) Ext 3	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences (all)	0	0	
Headache			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences (all)	0	0	
Somnolence			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences (all)	0	0	
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences (all)	0	0	
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences (all)	0	0	
Nausea			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences (all)	0	0	
Vomiting			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences (all)	0	0	
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences (all)	0	0	
Skin and subcutaneous tissue disorders			

Rash			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences (all)	0	0	
Psychiatric disorders			
Abnormal dreams			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences (all)	0	0	
Insomnia			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences (all)	0	0	
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences (all)	0	0	
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences (all)	0	0	
Upper respiratory tract infection			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences (all)	0	0	
Pharyngitis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences (all)	0	0	
Syphilis			
subjects affected / exposed	0 / 121 (0.00%)	0 / 111 (0.00%)	
occurrences (all)	0	0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
20 May 2015	AM1: Instructions to the Inclusion Criteria were added to direct investigators to provide appropriate guidance to subjects about the use of contraceptives after study completion. Modified Exclusion Criterion added to include the mutations D67N and K70R to those mutations indicative of resistance to emtricitabine, lamivudine, and tenofovir.
03 June 2015	AM2: Exploratory objective pharmacokinetics/pharmacodynamics changed to a secondary objective. Included updated list of medications prohibited during the use of ATRIPLA (EFV/FTC/TDF), and specified additional visits for the collection of plasma for potential viral resistance testing. Inclusion and Exclusion criteria added to include baseline hemoglobin threshold, and exclusion of subjects with severe hepatic impairment.
03 August 2015	AM3: Added text to explain the rationale for the selected doses of the lamivudine and TDF components of MK-1439A and include text to disallow concomitant use of interferon. Also clarified that sites would receive the calculated creatinine clearance in the laboratory reports from the central laboratory.
28 November 2016	AM4: Added open-label study extension 1 for 2 years to collect long-term efficacy and safety data. Clarified visits during which plasma samples were tested for resistance, and removed rosuvastatin as prohibited medication due to an interaction with DOR. Specified that concomitant medications prohibited due to interactions with EFV/FTC/TDF in the base study were allowed in the study extension.
05 February 2019	AM5: Added open-label study extension 2 to provide continued access to MK-1439A until the drug is available locally in countries participating in the trial or for an additional 2 years (whichever comes first). Added oxcarbazepine and rifapentine as prohibited medications/therapy due to interaction with MK-1439. Clarified that evaluation of Immune Reconstruction Syndrome (IRIS) causality applies only during the base study.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported